# Lesson 2: Histories: Ceremony, Canadian Psychiatry, Prohibition and Revival

*Companion-podcast transcript • Sarah & Kiffer*  
*Office Hours episode to listen to after working through the lesson*

---

**Sarah:** In the 1950s, Saskatchewan studies that followed patients for up to two years reported that fifty to ninety percent of people treated with LSD for alcohol use disorder had recovered. In 2012, when the randomized trials were pooled, the odds ratio at twelve months was 1.19, with an interval that included no effect.

**Kiffer:** So there are two popular ways to tell that history. In one, a promising treatment was shut down by politics before anyone could find out whether it worked. In the other, the early claims fell apart as soon as anyone ran a controlled trial.

**Sarah:** And each version leaves something out.

**Kiffer:** It does, and Sarah and I don't fully agree about how much.

**Sarah:** Welcome back to Office Hours. I'm Sarah.

**Kiffer:** And I'm Kiffer. We'll come back to that argument, because it sits in the middle of Lesson two, Histories: Ceremony, Canadian Psychiatry, Prohibition and Revival. The history starts centuries before any trial, though, so let's begin with ceremony.

**Sarah:** Before question one, a short content note, because this part discusses colonial harm to Indigenous communities, including the burning of a healer's house. If you'd like support, you can call or text nine eight eight, the Suicide Crisis Helpline, at any time. The Hope for Wellness Help Line for Indigenous people is at one eight five five, two four two, three three one zero. So, question one. When outside attention harmed María Sabina's community in Huautla, was the problem that money had entered a sacred practice?

**Kiffer:** That's a common reading, and the historical study behind this part of the lesson warns about it. Marcos Garcia de Teresa points out that Mazatec healers had long received payment, in goods or in cash, and that tourism now gives some families a modest income. The objection his sources record is to clients being deceived with excessive fees and false promises.

**Sarah:** So payment itself has a long history there. What changed after Wasson's article in 1957?

**Kiffer:** The scale changed, and so did control over it. In 1955 Wasson paid María Sabina fifty pesos, and his hosts turned down a larger gift, saying they did not do this for money. By 1960 she was charging four hundred pesos for ceremonies at a hotel, and a tour company was selling a package with two nights in Huautla. Wasson himself bought about one hundred twenty-five kilograms of mushrooms in 1958. Officials and conservative sectors of the community then blamed María Sabina for incidents involving foreigners, and her house was burned on several occasions.

**Sarah:** That's a steep rise from fifty pesos in five years, driven by demand from outside. And the blame landed on the healer who had received him.

**Kiffer:** Right. Publicity created demand, and the costs fell inside the community, which is the pattern the four questions from the lesson are meant to catch in any written account.

**Sarah:** Let me try them on something current. This is an advertisement I made up for this exercise, so it describes no real retreat. "Join an authentic ancient ceremony in the Amazon, guided by our founder, who has trained with traditional healers for ten years. One night can heal what years of therapy could not. Places are limited."

**Kiffer:** Go through the four questions in order. Who is speaking?

**Sarah:** The founder, selling a product. No healer and no community speaks at all. On consent, nothing shows that any community agreed to have its ceremony described or sold this way. The evidence is one sentence promising healing, with no comparison and no follow-up. And the benefits go to the company, while whoever bears the costs is invisible.

**Kiffer:** So here's a question for everyone listening. Celidwen and colleagues, an Indigenous-led consensus group, named four harms of commercialization: spiritual consumerism and exploitative tourism, unsustainable foraging, violence brought by drug cartels, and false information that a particular plant is the key to enlightenment. Which of those does this invented advertisement show most clearly? Take a few seconds, and pause the audio if you'd like more time.

*(Pause)*

**Sarah:** I'd pick the first. It's spiritual tourism managed by an outsider, which the group describes directly. The promise that one night can heal what years of therapy couldn't comes close to the fourth harm, too.

**Kiffer:** I agree, and I'd add a caution for my own side of the field. Researchers and clinicians can make the same move in a more respectable voice. An article that presents a ceremony as an ancient technique for treating depression offers outsiders a resource taken from a community, which is the kind of extraction the Indigenous-led group describes. The four questions apply to journal articles as much as to advertisements.

**Sarah:** And harm can come from people who mean well. On 30 March 2020, the National Council of Native American Churches and the Indigenous Peyote Conservation Initiative asked decriminalization campaigns not to name peyote in their resolutions.

**Kiffer:** Their reasons were practical. In the United States, peyote grows naturally only in a small area of southern Texas. The statement warned that naming it could create a false sense of legality and increase illegal harvesting. A campaign meant to protect people who use psychedelics can, in the view of the people whose sacrament it is, put that sacrament at risk. Canada's drug law already sets the plant apart, since Schedule III lists mescaline and expressly excludes peyote.

**Sarah:** Question two takes us to New Westminster. When two sources about Hollywood Hospital give very different numbers, how do you decide which to believe?

**Kiffer:** Start by asking what each one counts. The BC Archives description counts files and patients: five hundred ten surviving case files opened between 1957 and 1968, and index cards showing more than eight hundred patients. A magazine account reports more than six thousand supervised sessions between 1957 and 1975, and a success rate of fifty to eighty percent.

**Sarah:** And those can't both be counts of the same thing.

**Kiffer:** Here's a calculation worth walking into on purpose. Six thousand sessions divided by eight hundred patients is seven and a half sessions each. That sounds much more like the psycholytic model, with its five to twenty-five sessions, than the one or two high-dose sessions of the psychedelic model. Sarah, does that calculation hold up?

**Sarah:** It doesn't. The two numbers may not cover the same years, because the sessions run to 1975, the case files were opened up to 1968, and the archive doesn't date the index cards. More than eight hundred is a minimum taken from index cards, and only about two thirds of the files have been found. And the six thousand comes from journalism that drew partly on the hospital's own claims. Dividing one source's figure by the other's gives a ratio with no clear meaning.

**Kiffer:** Right. The success rate raises a different question: fifty to eighty percent compared with whom? The randomized trials give us a rough benchmark. In the five trials that reported yes-or-no outcomes, seventy-three of one hundred ninety-one control patients improved without a full dose of LSD. That's about thirty-eight percent.

**Sarah:** So if a clinic reported fifty percent success, a large share of that could have happened without the drug.

**Kiffer:** Possibly most of it, though the comparison is rough, because a private clinic's patients, its measure of success and its length of follow-up may all differ from the trials'. What the benchmark shows is that an improvement rate on its own can't tell you what a treatment added. You need to know what happened to similar people who didn't receive it.

**Sarah:** Question three stays with those trials. Summing the counts from the five trials gives a risk difference of about twenty points, while the meta-analysis reported sixteen. I know the meta-analysis compares groups within each trial first, but I want to see why summing goes wrong.

**Kiffer:** Let's build two made-up trials. Trial A runs in a program where many patients improve anyway, and it puts three patients on the drug for every one on control. On the drug, ninety of one hundred fifty improve, and on control, twenty-five of fifty. Trial B runs in a program where fewer patients improve, with equal groups. On the drug, thirty of one hundred improve, and on control, twenty of one hundred. Sarah, add the two trials together and work out the risk difference. Everyone else, try it too. Take a few seconds.

*(Pause)*

**Sarah:** Okay. On the drug, ninety plus thirty is one hundred twenty improved, out of two hundred fifty. One hundred twenty divided by two hundred fifty is 0.48. On control, twenty-five plus twenty is forty-five, out of one hundred fifty, which is 0.30. So the risk difference is eighteen percentage points, and the number needed to treat is one divided by 0.18, about five and a half.

**Kiffer:** Now compare that with each trial on its own.

**Sarah:** Trial A is ninety of one hundred fifty, sixty percent, compared with twenty-five of fifty, fifty percent. That's ten points. Trial B is thirty percent compared with twenty percent, also ten points. Hang on. Both trials show ten points, and my combined answer is eighteen. A combined answer can't be bigger than every result it combines.

**Kiffer:** That's the check that catches it. So where did the extra eight points come from?

**Sarah:** From the way the groups are built. Three fifths of the drug patients come from Trial A, where people improve more anyway, and two thirds of the control patients come from Trial B, where they improve less. Summing compares a mostly high-improvement group with a mostly low-improvement group, so part of my eighteen points is just the difference between the two programs.

**Kiffer:** That's it. Any sensible way of combining ten points with ten points gives ten points, which is a number needed to treat of ten, nearly double the five and a half from the summed counts. In the real trials, allocation was uneven too. The Madison trial, for example, assigned one hundred thirty-two patients to LSD and forty-four to no drug. That's one reason the within-trial estimate is the one to report.

**Sarah:** The trials also explain a conflict in the lesson. Passie and colleagues write that none of the controlled studies showed significant results in favour of psychedelic peak therapy for alcohol use disorder, while the pooled odds ratio at first follow-up clearly excludes one.

**Kiffer:** Both can be accurate if most trials were too small to show an effect on their own. With ten or twenty-two patients in a group, a real difference of fifteen points can easily miss significance. Pooling buys precision. What it can't do is turn six different treatments into one, from a patient held to the bed by a waist belt in Toronto to a prepared patient in a living-room setting in Baltimore.

**Sarah:** Before question four, another short content note, because this part discusses experiments on psychiatric patients who didn't consent, including prolonged drug-induced sleep and intensive electroshock. If you'd like support, you can call or text nine eight eight, the Suicide Crisis Helpline, at any time, and the Hope for Wellness Help Line for Indigenous people is at one eight five five, two four two, three three one zero. Question four. Is the history of consent in this lesson mainly a story about the CIA?

**Kiffer:** It's easy to file it that way. In 1977 the United States Senate heard that the surviving MKUltra records showed one hundred forty-nine subprojects, six of them involving tests on unwitting subjects. The program's records were destroyed in January 1973, and what survived were financial folders that had been sent to a records centre in 1970. So the counts describe what the surviving paperwork can show.

**Sarah:** Which makes them a minimum. We can't know what the destroyed records held.

**Kiffer:** That's a fair reading. In Montreal, at the Allan Memorial Institute, Ewen Cameron's depatterning combined prolonged drug-induced sleep with massive electroshock. From 1957 the CIA paid for part of his work through a front organization, Canada's federal health department also funded it, and patients and their families didn't know about the CIA's role.

**Sarah:** Here's a question for everyone. Two of the six randomized LSD trials in the twenty twelve meta-analysis concealed from patients that LSD might be used. Those were treatment trials, and the aim was to help patients. Does the first principle of the Nuremberg Code apply to them? Take a few seconds.

*(Pause)*

**Kiffer:** It does. The first principle says the voluntary consent of the human subject is absolutely essential, and it requires that the person know the nature, duration and purpose of the experiment and its hazards. A patient who doesn't know which drug might be given can't consent to it, whatever the investigator intends. Krebs and Johansen also noted that concealing the drug may have weakened the treatment and raised the risk of adverse events, so the ethical failure and the scientific weakness point the same way.

**Sarah:** And the standard was already written down. The Code dates from 1947, ten years before the CIA funding began, and Cameron had been among the psychiatrists sent to the Nuremberg trials. That makes the 1986 Cooper report's view, that depatterning was acceptable by the standards of its time, hard to accept.

**Kiffer:** I agree. Today's version of that standard shows up in Health Canada's expectations for psychedelic trials, published in December 2022. Written informed consent must be obtained before a person takes part, and consent for touch should be obtained before the drug is given and again at the moment of any touch. Consent is settled while the person is sober, then checked again during the session.

**Sarah:** One more number from this part. In 1992, Canada authorized payments of one hundred thousand dollars to people who had been depatterned. The Canadian Encyclopedia reports that seventy-seven were paid and more than two hundred fifty were denied. That means at least three quarters of claimants were turned down.

**Kiffer:** Two hundred fifty out of about three hundred twenty-seven is about seventy-six percent, so yes. The rule required proof of all three elements, prolonged sleep, massive electroshock and a mind reduced to a childlike state, and rejected applicants were told they hadn't been depatterned enough. In my view, a rule like that puts the burden of proof on the people whose memories the treatment damaged. In July 2025, the Superior Court of Québec authorized a class action that names the Government of Canada, the Royal Victoria Hospital and McGill University.

**Sarah:** Question five. The revival is often told as careful modern science replacing sloppy old science. Is that fair?

**Kiffer:** Partly. Some of the revival's most useful moments were corrections. In the Good Friday Experiment of 1962, twenty divinity students received psilocybin or nicotinic acid before a chapel service. Between 1986 and 1989, Rick Doblin tracked them down. He found that difficult experiences had been significantly under-emphasized in the original report, that one participant was given an injection of thorazine during the experiment with no mention of it, and that the blind broke as the psilocybin's effects deepened.

**Sarah:** And his follow-up has its own limits. He located nineteen of the twenty and interviewed sixteen, seven from the psilocybin group and nine from the control group. With ten in each group, that's seventy percent of the psilocybin group and ninety percent of the controls. In a group that small, the three psilocybin participants he didn't interview could change the picture a quarter of a century later.

**Kiffer:** That's a good catch, and it's the same scrutiny applied to the critic. Griffiths and colleagues addressed several of the older weaknesses in 2006, with individual sessions, an active comparison drug, methylphenidate, and open reporting that about a third of volunteers had significant fear. Then there's the 2002 study in Science that reported severe damage to dopamine neurons in primates given MDMA. It was retracted in 2003, because the drug given to all but one animal came from a bottle that contained methamphetamine.

**Sarah:** And the authors attributed that to a labelling error, so a retraction can follow an honest mistake.

**Kiffer:** Yes, and the lesson for readers runs in both directions. A claim of harm deserves the same scrutiny as a claim of benefit, and a single animal study tells us little about people until it's replicated. Each of these corrections happened because someone went back and checked what was reported, who was missing, or what was in the bottle.

**Sarah:** Okay. Now the part where we disagree, which takes us back to the start. Was LSD for alcohol use disorder a working treatment that prohibition buried?

**Kiffer:** You go first, since you lean further toward yes than I do.

**Sarah:** Toronto's Alcoholism and Drug Addiction Research Foundation disputed the Saskatchewan results and asked for controlled trials. By 1970, several randomized trials had been published, and a twenty twelve meta-analysis combined six of them. Pooled, the odds of improvement at first follow-up were about twice as high with LSD, with a number needed to treat of six, from a single session. That's a respectable effect. And Erika Dyck gives two reasons the research ended: stricter trial standards, and LSD's growing link with the counterculture, which led governments to criminalize it. That second reason had little to do with the trial results.

**Kiffer:** I agree the politics were real. Where I'd push back is on the word working, so let's put the odds ratios into people. About thirty-eight percent of control patients improved at first follow-up. Sarah, with an odds ratio of 1.96, what share would improve with LSD?

**Sarah:** The control odds are thirty-eight divided by sixty-two, about 0.61. Times 1.96 is about 1.2. To turn odds back into a risk, divide by one plus the odds, so 1.2 divided by 2.2, which is about fifty-five percent. That's a difference of about seventeen points, close to the sixteen the meta-analysis reported.

**Kiffer:** Good, the check works. Now twelve months. The control rate at twelve months isn't one of the figures we have, so suppose, hypothetically, it was still thirty-eight percent. The odds ratio was 1.19, with an interval from 0.74 to 1.90. Before any arithmetic, what does it tell you that the interval goes below one? Take a few seconds.

*(Pause)*

**Sarah:** That at twelve months the data fit LSD doing a little worse than control, about the same, or quite a bit better, and the trials can't tell those apart.

**Kiffer:** Here's what that looks like in people, with our hypothetical thirty-eight percent. An odds ratio of 1.19 gives about forty-two percent improved, four points more, a number needed to treat of about twenty-four. The upper limit, 1.90, gives about fifty-four percent, sixteen points more. The lower limit, 0.74, gives about thirty-one percent, seven points fewer. So at a year, the evidence fits anything from slight harm to the full early benefit. I'd describe it as a short-term benefit that deserved more testing, and I'd stop short of calling it a working treatment.

**Sarah:** But fading after a year isn't surprising for a single session. Every trial gave one dose to people already in alcohol treatment programs. If the benefit fades after one session, that raises a question about follow-up care, and modern trials with integration sessions could help answer it.

**Kiffer:** That's a fair hypothesis, and I'd like to see it tested. I'd add that blinding is hard with a drug this strong, and the comparisons ranged from no drug at all to a low dose of LSD, so expectancy may explain some of the early effect, which Lesson five takes up. Overall, I think the history justifies new trials, and I'd want those trials to report the twelve-month result as prominently as the first follow-up.

**Sarah:** I still think politics did more of the burying than Kiffer does, but we agree on the practical rule. When someone tells you a treatment was buried or debunked, ask for the time point, the interval and what happened to the comparison group.

**Kiffer:** Let's pull it together with three things to take away.

**Sarah:** First, when you read any account of a ceremonial tradition, ask who is speaking, whether the community consented and who bears the costs. In Huautla, harm followed publicity the community didn't control, and the blame fell on its healer.

**Kiffer:** Second, before trusting a number from history, ask what it counts and what it's compared with, because sessions differ from patients, summed trials can mislead, and about thirty-eight percent of control patients in the trials improved too.

**Sarah:** And third, the requirements of consent and honest reporting apply to every study, whoever funds it. The Nuremberg Code applied to therapeutic trials that concealed the drug as much as to the CIA, and the revival's credibility has depended on checking its own record.

**Kiffer:** If you'd like more practice, rework the two made-up trials from question three with equal groups of one hundred in Trial A, keeping the same improvement rates, and see whether summing the counts still gives the wrong answer.

**Sarah:** Next time, it's Lesson three, Pharmacology of Psychedelics: Receptors, Pharmacokinetics, Dose and Interactions, where we turn from history to how these drugs act at receptors and in the body.

**Kiffer:** Take care, everyone.

**Sarah:** See you in Lesson three.
